



China Economic Perspectives

China by the Numbers (June 2024)

Economics

China

Our guide to Chinese monthly data

What the numbers are, what they mean, and the outlook going forward.

Mixed growth momentum in May

The recovery in May retail sales growth exceeded market expectations, albeit from a low base, and manufacturing fixed asset investment (FAI) remained robust. [Export growth picked up strongly](#) on the global tech upcycle and resilient external demand. However, property activities remained in deep contraction YoY with seasonally adjusted property sales and new starts slightly down from April and Q1. Housing price decline accelerated a bit in May. Infrastructure FAI softened YoY on weak local government (LG) fiscal conditions and restricted LGFV financing. Industrial production growth moderated more than the market expected, as soft domestic activities more than offset solid export demand. On a five-year CAGR, most economic activities (excl property) remained largely stable or recorded slightly better momentum than in April, but were still weaker than in Q1. See more in [our comment](#).

Further policy easing is needed

Despite policy easing in mid-May, [property sales have yet to recover meaningfully](#) notwithstanding short-lived improvement around end-May, suggesting the impact of recent policy easing is likely diminishing. The PBC rolled out a new re-lending facility to support property destocking, but progress appears limited. We believe the government needs to further facilitate destocking with more low-cost funding, and possibly top-down guidance to clarify implementation details from central government. Meanwhile, the government is expanding its ['whitelist' scheme](#) to support stalled property projects. Fiscal policy support has picked up since May, which should help to underpin infrastructure investment and overall credit growth, although we still see slower infrastructure FAI growth in 2024E. If overall growth momentum disappoints and property activities weaken further, we expect more policy support measures to be rolled out, possibly around or after the July Politburo meeting.

CFOs expect higher US tariffs and negative impact

With the US election coming up in a few months and former president Donald Trump reportedly considering further tariffs on Chinese goods, 85% of CFOs in UBS Evidence Lab's [13th China CFO survey](#) expect higher US tariffs in 2025, although most expect them to be lower than 60%. In response to the shock, surveyed firms mostly plan to explore non-pricing channels, diverting products to other markets or domestically, reducing capex and wages, or closing factories. But even so, 78% of manufacturing exporters believe their export-related businesses could fall. Escalated trade frictions will also promote further supply chain shifts overseas. We believe a new trade war with much higher US tariffs in 2025 is a clear downside risk to China's growth next year.

GDP QoQ growth to slow in Q2, but lower base to support YoY growth

Our base case remains that property sales may bottom in the next few months, helped by ongoing policy easing. A weak labour market recovery and subdued income expectation suggest lingering headwinds for a consumption recovery, while we expect solid YoY export growth in June and early Q3. Overall, we expect sequential GDP growth to slow in Q2 from the strong Q1, although YoY growth may remain at around 5.3% due to the low base. We expect growth momentum to stabilise at 4-5% in H2, leading to [full-year GDP growth of 4.9%](#). However, we flag some downside risks to our base case forecasts if additional property policy easing (especially inventory destocking) is weaker and later than expected, and property sales and prices decline much further.

Jennifer Zhong

Economist

jennifer-a.zhong@ubs.com

+86-105-832 8324

Grace Wang

Economist

S1460524050003

grace-zc.wang@ubs.com

+86-105-832 8335

William Deng

Economist

william-w.deng@ubs.com

+852-2971 6765

Ning Zhang

Economist

ning.zhang@ubs.com

+852-2971 8135


Tao Wang

Economist

wang.tao@ubs.com


+852-2971 7525

Figure 1: Credit growth edged up but missed expectations in May




Source: CEIC, UBS estimates

Figure 2: Retail sales edged up on low base, better than expected




Source: CEIC, UBS estimates

Figure 3: Overall FAI growth largely stable y/y, with softer infrastructure and robust manufacturing FAI




Source: CEIC, UBS estimates

Figure 4: Property activities remained in deep y/y decline




Source: CEIC, UBS estimates

Figure 5: CPI remained stable and PPI declined less y/y, both largely in line



Source: CEIC, UBS estimates

Figure 6: UBS China Activity Index



Source: CEIC, Wind, G7, China Port Association, UBS estimates

Table of Contents

Activity Indicators	4
UBS Physical Activity Index	
UBS Expenditure Index	
Business Indicators	5
NBS and Caixin PMI	
Other business climate indices	
Property	6
Property indicators and UBS construction index	
Property inventory	
Fixed Asset Investment	7
FAI by components	
Infrastructure	
Industrial Production	8
Industrial Production	
Industrial inventory	
Consumption	9
Retail sales	
Household income and consumption	
Inflation	10
CPI	
PPI	
Money & Credit	11
Money and credit growth	
UBS credit impulse	
Base Money & Liquidity Operations	12
Base money growth	
PBC liquidity provisions	
Interest Rates & Bond Market	13
Rates and yields	
New bond issuance	
Trade	14
Exports and imports	
China's market share	
FX Reserves & Capital Flows	15
FX reserve breakdown	
Non-FDI outflows	
Exchange Rate	16
CNY against USD and basket	
Exchange rate expectations	
Financial Markets	17
A/H share market	
Sector performance	
Fiscal	18
Fiscal revenue and land sales	
PPP projects	
Data Tables	19

Source: UBS

UBS Activity Indicators


- **UBS Physical Activity Index moderated to 3.6%y/y in May** from 4.9%y/y before on 3mma basis, mainly dragged by slower industrial production and continued weakness in construction, which more than offset improving transportation activities.
- **UBS Expenditure Index edged up in May**, o/w investment and consumption both picked up while net exports growth moderated on 3mma basis from April.
- **Our high frequency data tracker** shows 30-city new property sales remained in contraction of -29% y/y in the first 22 days of June from -38% y/y in May. New home sales volume in high-tier cities moderated in the first 22 days (partly due to seasonality, Fig 2-3) from a short-lived uptick in the last 10 days in May (on policy easing), although it rebounded modestly again in the past week. FTL traffic index declined further to -6%y/y in the first 22 days from -2%y/y before. Subway passenger turnover remained elevated, while its growth decelerated slightly to 7%y/y in the first 20 days from 9%y/y. Auto retail sales weakened to -13%y/y in the first 16 days from 10%y/y despite a low base. Port cargo throughput growth moderated to 5% y/y in the first 16 days, while container throughput growth picked up to 11% y/y. In the past week (June 17-23), net issuance of CGB slid to a decline of RMB 108bn, while that of special LGB remained weak at RMB 2bn (see [UBS China Daily Activity Tracker](#)).

Figure 7: UBS Physical Activity Index




Source: CEIC, UBS estimates *chart is 3mma basis

Figure 8: Construction and industry




Source: CEIC, UBS estimates *chart is 3mma basis

Figure 9: UBS Expenditure Index




Source: CEIC, UBS estimates *chart is 3mma basis

Figure 10: Li Keqiang Index




Source: CEIC, UBS estimates. Note: Our Li Keqiang index uses industrial power consumption and new corporate M&L loans, not total RMB lending and total power generation.

Figure 11: UBS China Activity Index



Source: CEIC, Wind, G7, China Ports Association, UBS estimates

Figure 12: Full Truck Load (FTL) Freight Traffic Index




Source: Wind, G7, UBS estimates. Note: G7 revised the statistical approach after June 26th 2023

Business Indicators


- May NBS manufacturing PMI slid by 0.9ppt to 49.5**, much lower than expected. New orders fell by 1.5ppt to 49.6, while production index dipped by 2.1ppt to 50.8. New export orders weakened by 2.3ppt to 48.3. Raw material inventory edged down by 0.3ppt to 47.8, while quantity of purchased and finished goods dropped by 1.2ppt/0.8ppt to 49.3/46.5. Input and output prices both increased by 2.9ppt and 1.3ppt to 56.9 and 50.4, respectively, indicating an easing of deflationary pressures. Employment edged up by 0.1ppt to 48.1, reflecting lingering labour market pressures. In contrast, **Caixin PMI picked up further by 0.3ppt to 51.7**, with stronger production index (+1.2ppt) but softer new orders (-0.4ppt). Such divergence between NBS and Caixin PMIs is not uncommon, largely due to the difference in survey sample selection, while we may need other high frequency data points to cross-check the underlying strength of the manufacturing sector.
- NBS non-manufacturing PMI edged down by 0.1ppt to 51.1**, while remaining above 50 consistently since January 2023. In particular, services PMI edged up by 0.2ppt to 50.5, while construction PMI cooled by 1.9ppt to 54.4, reflecting decelerating momentum of construction activities. By sector, PMIs of postal, telecom /TV / satellite, internet / software / IT, cultural /sports / entertainment services remained above 55; while those of the capital market and real estate sector remained subdued.

Figure 13: NBS and Caixin PMI




Source: CEIC, UBS estimates

Figure 14: NBS PMI breakdown




Source: CEIC, UBS estimates

Figure 15: Caixin PMI breakdown




Source: CEIC, UBS estimates

Figure 16: Input prices




Source: CEIC, UBS estimates

Figure 17: NBS non-manufacturing PMI



Source: CEIC, UBS estimates

Figure 18: Other business climate indices




Source: CEIC, UBS estimates

Note: Both sets of PMIs have different sample sizes & coverage – Caixin's PMI covers ~420 enterprises and is more biased to eastern regions and smaller enterprises. The official NBS PMI covers >3,000 enterprises nationwide, with more large companies represented. The NBS PMI sample coverage was expanded from 820 to 3,000 in Jan 2013, which may undermine its comparability with historical data, making it harder to interpret the results of our additional layer of seasonal adjustments.

Property

- Property sales remained deep in contraction y/y.** Despite recent policy easing in mid-May, property sales continued to decline notably by 20.7% y/y (albeit slightly better than -22.7% in April on a low base), while new starts contracted further by 22.7% y/y (vs -14% y/y previously). After seasonal adjustments, new starts and property sales volumes dipped a bit further in May from April and the Q1 average. Property completions remained weak at -18.4% y/y (vs -19.1% y/y in April), as did property investments at -11% y/y (vs -10.5% previously). Developers' source of funds remained deep in contraction at -21.8% y/y. Moreover, the decline in 70-city housing prices deepened in May.
- Property sales volumes to stabilise in the coming months; downside risks remain.** A combination of [weakening fundamentals](#), previous policy tightening, and [subdued home purchase intentions](#) has driven the current sharp property downturn. The government started to [ease policies in Q4 2022](#) and more notably after the [July 2023 Politburo meeting](#). The [April 2024 Politburo meeting](#) called for ensuring housing delivery and destocking. On 17 May 2024, the government [relaxed property policies further](#) by lowering the minimum down payment ratio, removing the minimum mortgage rate requirement, and calling for more support for stalled projects and property inventory destocking. That said, new home sales remained weak in June after a short-lived rebound in end-May, while secondary listings remained elevated, suggesting a diminishing effect from demand-side policies. The PBC rolled out a new re-lending facility to support property destocking, but progress appears limited thus far. We believe the government needs to provide more low-cost funding and roll out top-down guidance to clarify implementation details. Our baseline remains that property sales and new starts will likely bottom in the next few months, with the help of ongoing policy easing. Overall, we expect property sales/starts/investment to fall by 5-10%/15-20%/5-10% in 2024, respectively, vs -8.5%/-20.4%/-9.6% in 2023.

Figure 19: Property activities remained in deep decline y/y




Source: CEIC, UBS estimates * chart is 3mma basis

Figure 20: Mortgage easing since 2022




Source: CEIC, UBS estimates

Figure 21: Property construction vs steel & cement demand




Source: CEIC, UBS estimates * chart is 3mma basis

Figure 22: Property activities weakened sharply since Q2 2023




Source: CEIC, UBS estimates * chart is 3mma basis

Figure 23: 'Urban village' renovations are not the same as shanty-town renovations



Source: CEIC, UBS estimates

Figure 24: Inventory/sales ratio remained elevated




Source: CEIC, Wind, Soufun, UBS estimates

Fixed Asset Investment


- Overall FAI growth largely stabilized at 3.5% y/y in May.** Infrastructure FAI growth softened to 3.8% y/y in May from 5.9% y/y in April. While the issuance of 2024 special CGB and LGB accelerated in May, disbursement to local projects takes time. Meanwhile, the slow pace of government bond issuance previously, weak local land sales and tight control of LGFV debt may have weighed on overall financing of infrastructure FAI. On a five-year CAGR basis, infrastructure FAI growth edged up to 5.4% y/y from 5.1%. Meanwhile, manufacturing FAI growth held up robustly at 9.4% y/y in May (with the 5-yr CAGR edging up to 5.7%), partly due to continued policy support including equipment upgrading & replacement. Considering the continued decline of property investment, overall FAI growth largely stabilised at 3.5% y/y in May, with its CAGR edging down by 0.2ppt to 4%.
- We expect both infrastructure and manufacturing growth to slow in 2024.** The central government plans to provide more explicit support to infrastructure FAI, with RMB1trn of special CGB and RMB3.9trn of special LG bonds in 2024. However, LGFV financing remains restricted, while local land sales are still under pressure. We expect full-year infrastructure FAI growth to slow to 5-6% in 2024 (vs 8.2% in 2023) with downside risks. We see further growth potential in new energy investment, hydraulic & water projects, city-cluster transport networks and public utility and facilities. In the manufacturing sector, we believe FAI in the sectors along the property supply chain will likely be held back by weak demand and profits, although FAI related to the green transition should remain robust, whereas FAI along the tech supply chain could improve. An export recovery could also support manufacturing FAI. Overall, we expect 5-6% growth in manufacturing investment in 2024 (6.5% in 2023). See more in our [2024-25 outlook](#).

Figure 25: Overall FAI growth largely stabilised in May




Source: CEIC, UBS estimates

Figure 26: Infrastructure FAI growth cooled




Source: CEIC, UBS estimates. *chart is 3mma basis

Figure 27: Manufacturing capex held up in May




Source: CEIC, UBS estimates. *chart is 3mma basis

Figure 28: Private FAI tends to mirror property & manufacturing FAI



Source: CEIC, UBS estimates

Figure 29: Infrastructure investment breakdown




Source: CEIC, UBS estimates. *chart is 3mma basis

Industrial Production


- Industrial production (IP) growth edged down to 5.6% y/y in May.** The official seasonally adjusted IP level edged up by 0.3% m/m in May, slowing from 1% m/m in April. We estimate the five-year CAGR of IP remained largely stable at 4.6%. By sector, value added (VA) growth of the auto sector slid to a still solid pace of 7.6% y/y (vs 16.3% previously) and auto production softened, both on a high base. VA growth of communication appliances remained robust at 14.5% y/y (vs 15.6% previously) due to the global tech upcycle and robust external demand, while production growth of electronic ICs decelerated to a still solid pace. In addition, y/y growth of ferrous metal VA and steel production both improved, while that of non-metal minerals VA and cement production turned only slightly less bad.
- China's inventory growth edged up further in April,** to 3.1% y/y in nominal terms (vs 2.5% y/y previously) and to 5% in real terms (vs 4.9% previously). Industrial inventory-to-sales ratio (seasonally adjusted, 6mma) has risen notably since 2022, now still well above the historical average, which means destocking will take a few more months.

Figure 30: Industrial sales growth improved in April




Source: CEIC, UBS estimates * chart is 3mma basis

Figure 31: Industrial production edged down in May, partly due to holiday effect




Source: CEIC, UBS estimates

Figure 32: Inventory growth edged up y/y in nominal terms in April...



Source: CEIC, UBS estimates

Figure 33: ... while on flow basis it picked up too




Source: CEIC, UBS estimates. Note: above chart is on a 6-month average, real, seasonally adjusted basis.

Consumption


- Retail sales picked up to 3.7% y/y in May from 2.3% y/y in April.** We estimate May's seasonally adjusted retail sales level (in both nominal and real terms) edged up from April, as did the official estimate (nominal terms). In addition to a lower base, the shift in timing of the Labour Day holiday meant two more public holidays (excluding weekend) in May 2024 than a year ago, which likely helped support retail sales y/y growth slightly. The five-year CAGR of nominal retail sales growth improved to 3.6% (vs 3.2% in April), suggesting slightly better underlying growth momentum. By key category, goods retail sales improved with auto sales narrowing its y/y contraction. Among property-related products, sales of construction materials remained weak, while those of furniture and household appliances improved, the latter also boosted by a low base effect. Going-out related products (cosmetics, clothing, sports goods) picked up y/y on a low base. Meanwhile, catering sales edged up, while YTD services sales growth moderated.
- Consumption recovery should continue at a slightly slower pace in 2024.** China's post-COVID consumption recovery in 2023 lagged that in other economies due to subdued income growth recovery and weak consumer confidence. Our estimated real retail sales and the official consumer confidence level bottomed around Q323 and have been improving, but only slightly, since then. The official unemployment rate appears to have largely stabilised, while our [labour market survey](#) indicated continued pressures on the labour market and income growth. Later in the year, the expected stabilisation in property activities should prevent household confidence from sliding further. That will likely help to support a continued post-COVID consumption recovery, although at a slower pace. In Q124 the household savings rate remained above the pre-COVID 2019 level by 2ppt, indicating lingering cautious consumer sentiment and further accumulation of [excess savings](#). Overall, we expect annual real consumption (GDP basis) to slow to 5.1% in 2024, from 6.4% in 2023.

Figure 34: Retail sales edged up y/y in May on a low base




Source: CEIC, UBS estimates *chart is 3mma basis

Figure 35: Auto sales narrowed y/y decline




Source: CEIC, UBS estimates

Figure 36: China's retail sales recovery still has a long way to go




Source: CEIC, UBS estimates

Figure 37: Real household income cooled a bit y/y in Q1...



Source: CEIC, UBS estimates

Figure 38: ... as did real consumption growth




Source: CEIC, UBS estimates

Inflation


- **Headline CPI held stable at 0.3% y/y in May.** Food inflation narrowed its contraction by 0.7ppt to -2%y/y, mainly driven by supply shocks in the form of heavy rains in Southern China and lower pork supply. Sequential price uptick and a lower base pushed pork price growth up to 4.6% y/y (vs 1.4% previously). Contrastingly, non-food prices softened y/y and declined by 0.2% m/m, with touring outgoing prices falling by 0.6% m/m on fading travelling demand after early May holidays. Utility prices saw another flat sequential m/m growth in May, despite news of utility price hikes in some localities.
- **PPI turned less negative by 1.1ppt to -1.4% y/y on a low base,** and rose sequentially by 0.2% m/m (vs -0.2%m/m before), partly due to rising global commodity prices. Investment goods picked up by 1.5ppt to -1.6% y/y (0.4% m/m before), of which the mining and quarrying price narrowed its decline, raw materials turned positive y/y, and the manufacturing price improved to -2.6% y/y. PPI consumer goods edged up to -0.8% y/y (-0.1% m/m).
- **We expect positive but soft CPI inflation in 2024.** We continue to expect non-food consumer goods prices to increase slightly and pork prices to bottom out gradually in the rest of 2024. **Full-year CPI may only print 0.4% y/y in 2024** (vs 0.2% in 2023), given YTD softness, robust production activities and slow recovery of domestic demand. Manufacturing and consumer goods under PPI could remain soft in the coming months given the relatively low capacity-utilisation rate. Raw materials prices may stabilise gradually after a sharp decline since the end of 2023. We therefore expect PPI to remain in y/y contraction in most of 2024 and turn positive y/y only in early 2025, printing **a full-year contraction of 1-1.5%** (from -3% y/y in 2023).

Figure 39: CPI and PPI




Source: CEIC, UBS estimates

Figure 40: Food / non-food inflation




Source: CEIC, UBS estimates

Figure 41: Food CPI by component




Source: CEIC, UBS estimates

Figure 42: Non-food CPI by component




Source: CEIC, UBS estimates

Figure 43: Upstream price indices



Source: CEIC, UBS estimates

Figure 44: PPI by component




Source: CEIC, UBS estimates

Money & Credit


- New credit missed expectations and M1 decline deepened.** The headline new RMB loans recorded RMB 950bn in May (-RMB410bn y/y), lower than the market expected. Similar to April, bill financing is the only component stronger than it was a year ago, while M&L corporate loans (at RMB 500bn, -RMB 270bn y/y) and M&L household loans (at RMB 51bn, -RMB 117bn y/y) were both lower than they were last May. The former illustrated soft credit demand from corporates, while the latter echoed subdued property sales. Meanwhile, net issuance of government bonds picked up notably to RMB 1.2trn as expected, much higher than a year ago (+RMB 668bn y/y). The official TSF growth and our adjusted TSF growth (excl equity) edged up by 0.1-0.2ppt to 8.5-8.6% y/y in May, while credit impulse declined less. M1 growth declined deeper to -4.2% y/y, dragged by a -7.2% y/y decline in corporate demand deposits partly on regulatory tightening and soft corporate cash flows. See more in [our comment](#).
- Credit demand may improve modestly in the rest of 2024.** We believe faster government bond issuance in the next few months should underpin credit growth. Corporate credit demand may also improve later in the year as growth momentum and property activities stabilise. That said, the new GDP estimation methodology and tighter financial regulation will continue to suppress credit growth in the rest of 2024. We believe this, plus weak corporate credit demand in general, may limit overall credit growth rebound to about 9% y/y at end-2024.

Figure 45: M1 saw deeper y/y decline of -4.2% y/y in May




Source: CEIC, UBS estimates

Figure 46: New TSF came in softer than expected




Source: CEIC, UBS estimates

Figure 47: Banks' domestic claims on NBFIs edged down




Source: CEIC, UBS estimates

Figure 48: TSF growth edged up in May, but missed expectation




Source: CEIC, Wind, UBS estimates

Figure 49: New credit flows held stable on 3mma basis



Source: CEIC, UBS estimates *chart is 3mma basis

Figure 50: Credit impulse turned less negative




Source: CEIC, UBS estimates

Note: PBC changed TSF statistical coverage in Jul 2018 by including banks' ABS and loan write-offs, in Oct 2018 by including special LG bond, in Oct 2019 by adding ABS listed in exchange markets into corp bonds, and in Jan 2020 to include general LG bonds and treasury bonds

Base Money & Liquidity Operations


- **Base money growth slid by 1ppt to 3.8% y/y in May** (3mma), after adjusting for RRR cuts (eg, Jan 2020, July/Dec 2021, Apr/Dec 2022, Mar/Sep 2023, Feb 2024 and various targeted RRR cuts) and changes from other liquidity facilities.
- **The PBC injected liquidity in the interbank market in May.** The PBC injected RMB 70bn in liquidity in May, with RMB 164bn via open market operations (OMO), which offset the modest liquidity withdrawal of RMB 75bn through PSL (Pledged Supplementary Lending). Nevertheless, interbank rates hovered within a narrow range, suggesting largely stable liquidity conditions. The PBC cut RRR by 50bp on 5 February, which brought down the overall weighted average RRR for financial institutions to 7.0% from 7.4% and released base money liquidity of around RMB1trn, helping to keep overall liquidity ample (see [RRR cut comment](#)).
- **We expect continued accommodative monetary and credit policy, but no aggressive easing.** We expect the PBC to ensure ample liquidity by possibly cutting RRR once more and the use of other liquidity facilities in 2024, to accommodate the expected large bond issuance.

Figure 51: Base money growth on 3mma basis




Source: CEIC, UBS estimates *chart is 3mma basis

Figure 52: PBC liquidity provisions




Source: CEIC, Wind, UBS estimates

Figure 53: PBC cut RRR by 50bp in Feb, lowering the average RRR to 7.0% from 7.4% previously



Source: CEIC, UBS estimates

Figure 54: PBC injected liquidity modestly in May




Source: CEIC, UBS estimates

Interest Rates & Bond Market


- **REPO rate unchanged in 2024.** Interbank rates typically move up toward month-end on seasonal liquidity demand and edge down at the start of the following month. The PBC cut the Reverse REPO rate by 20bp in 2023 and has kept it unchanged in 2024 thus far. DR007 averaged 1.94% in 2023 and recently hovered around 1.8-1.9%.
- **Yields edged down as property downturn deepened.** 10-year CGB yield trended down since Q2 2023 due to subdued growth momentum, except for a period of modest rebound in Aug-Oct 2023 on signs of growth bottoming. Since late 2023, 10yr CGB yield has trended down again on expected policy easing and investors' preference for safety assets, hovering around 2.2-2.3% recently. Corporate yields dropped as well, and corporate credit spreads narrowed modestly. May issuance of government bond picked up pace, as expected.
- **Likely no policy rate cut in 2024.** In 2023, the PBC cut the MLF rate by 25bp, 1yr LPR by 20bp and 5yr LPR by 10bp. Commercial banks were asked to lower rates of outstanding mortgages and deposit rates. In Feb 2024, the PBC cut 5yr LPR by 25bp without cutting the MLF rate. In light of strong USD and expectations of a Fed rate cut only in Q424, we do not expect the PBC to cut MLF policy rates this year. We think there may be room to guide banks' LPR rate down by another 10-20bp alongside further reductions in bank deposit rates.

Figure 55: REPO rate was cut by 10bp in August 2023 and kept unchanged since




Source: CEIC, Wind, UBS estimates. NB: R007 is the average 7-day repo traded by all FIs, whereas DR007 is the 7-day repo only traded by depository institutions making it a less volatile benchmark.

Figure 56: 10y CGB yield softened to around 2.2-2.3% recently




Source: CEIC, Wind, UBS estimates

Figure 57: Corporate bond yields also declined



Source: CEIC, Wind, UBS estimates

Figure 58: Net issuance of all bonds and corporate bonds




Source: Wind, UBS estimates

Trade


- **Exports accelerated to 7.6% y/y growth in May, from 1.5% in April.** Import growth moderated to 1.8% y/y. The monthly trade balance widened to USD 82.6bn in May from USD 72.4bn in April. Taking 2019 as the base, exports and imports grew by 7.2% and 4.9% in May, vs priors of 8.6% and 4.0%, respectively. Full-year exports contracted by 4.6% y/y and imports by 5.5% y/y in 2023, after growing 5.6% and 0.7% in 2022. Real exports and imports expanded by 4.6%/2.9% in 2023.
- **Shipments to the US bounced back to growth; IT exports growth accelerated.** Shipments to the G3 (the US, the EU and Japan) registered 1.2% y/y growth in May vs a 2.9% y/y contraction in April, due to an upswing in shipments to the US. Export growth to ASEAN economies outperformed again, with y/y shipment growth accelerating to 21.3% y/y. Consistent with the tech upcycle, shipment growth of the IT basket accelerated to 13.7% y/y in May (from prior of 11.4%). Shipments of consumer goods returned to 1.6% y/y growth in May, after y/y contractions in the previous two months.
- **A slight trade recovery in 2024.** Trade growth data from neighbouring economies continued to suggest steady momentum of external demand. Contrastingly, survey data displayed a softening bias. In our view, current data combinations suggest the external demand recovery has continued for China into Q224 with steady sequential momentum, although there is still limited evidence to suggest a boom for export demand. Given the statistical base is turning lower for the coming months, we believe the steady sequential momentum should support exports to remain in y/y growth. We expect full-year exports to record 3.5% y/y in 2024 (vs -5% in 2023, see [latest view](#)).

Figure 59: Exports accelerated further in May




Source: CEIC, UBS estimates *chart is 3mma basis

Figure 60: Import growth softened




Source: CEIC, UBS estimates *chart is 3mma basis

Figure 61: Average annualised trade growth since 2019




Source: CEIC, UBS estimates

Figure 62: Key commodity imports




Source: CEIC, UBS estimates *chart is 3mma basis

Figure 63: Contribution to change in trade balance by product



Source: CEIC, UBS estimates *chart is 3mma basis

Figure 64: China's market share likely peaked in Q2 2020




Source: CEIC, UBS estimates

FX Reserves and Capital Flows


- **Headline FX reserves expanded by USD 31.2bn to USD 3.23trn in May vs April.** China's FX reserves increased by USD110bn in 2023, declined by USD 123bn in 2022, and increased by USD 34bn in 2021, following gains in 2019-20 and losses in 2018.
- **Valuation effect turned positive; widening trade balance provided support.** We estimate the positive valuation effect from major reserve currencies' movements in May has likely been around USD 15bn due to incremental USD weakness at end-May vs end-Apr. Global financial market fluctuations might have brought additional valuation gains too, but a widening trade balance vs Apr should have offered some support as well. Overall, capital outflow pressure has likely continued in May, following a net inflow in Q124. Meanwhile, the balance of total foreign holdings of China's onshore bonds registered another expansion of RMB 51bn in April, after gaining RMB 328/474bn in Q124/Q423. Foreign holding balance recorded a RMB 282bn gain in 2023 (contractions in most of the early months but turning positive since Sep), after a RMB 616bn loss in 2022.
- **We expect the new normal to continue**, with larger two-way capital flows. The rise in capital outflows will mainly reflect non-government entities' accumulation of overseas assets, especially as controls on capital outflows gradually ease over the longer term. Continued [supply chain shifts overseas](#) will also drive outward direct investment (ODI). The recent sharp drop in foreign direct investment (FDI) into China is partly due to a decline in retained profits and high USD costs, but also reflects pressures of decoupling. We expect FDI to [recover in 2024-25](#), but not back to pre-pandemic levels. Meanwhile, we believe the continued opening of China's financial market and solid economic growth potential should continue to attract more inflows (see our [deep dive](#)).

Figure 65: Headline FX reserves balance expanded in May...




Source: CEIC, UBS estimates

Figure 66: ... partly due a weaker USD




Source: Wind, UBS estimates

Figure 67: Export/import conversion ratio




Source: CEIC, Wind, UBS estimates

Figure 68: Non-FDI capital outflows may have continued



Source: CEIC, UBS estimates

Figure 69: Breakdown of change in FX reserves




Source: CEIC, UBS estimates

Exchange Rate


- RMB remained largely unchanged in the range of 7.24 against the USD comparing end-May to end-Apr.** That said, the RMB depreciated more in the 2nd half of May, giving up gains from the first half, and softened further in recent days. The CNY depreciated by 0.7% against the CFETs basket over May. In 2023, full-year RMB weakened by 2% vs USD, and strengthened by 1% against the basket. This followed 9% depreciation vs the USD and 2.4% weakness vs the basket in 2022.
- RMB exchange rate has been driven by various factors.** Resilient trade balance is a supporting factor, while the negative China-US rate differentials and concerns on China's growth momentum slowdown are main headwinds. The PBC lowered RRR for FX deposits by 200bp/100bp in Sep/Apr 2022. The SAFE raised the macroprudential adjustment parameter for cross-border financing from 1 to 1.25 in Oct 2022, and further to 1.5 in July 2023.
- RMB may strengthen to 7.1-7.2 range by end 2024E.** Similar to the recent depreciations, the dynamics of the interest rate differentials, USD index, as well as China's growth data and property market weakness, may still bring episodes of CNY weakness ahead. That said, the PBC will likely use various tools (including counter-cyclical factor in daily fixing) to prevent further CNY weakness much beyond 7.3, amid rapid episodes of depreciation and significant increases in volatility. Given our expectation of stabilisation in China's growth momentum as well as expected US Fed interest rate cuts, we continue to expect RMB to strengthen a bit by end-2024E to 7.1-7.2.

Figure 70: CNY vs USD depreciated more in the 2nd half of May




Source: Wind, UBS estimates

Figure 71: CNY weakened in REER terms in 2022 and 2023




Source: CEIC, UBS estimates

Figure 72: RMB vs competitor currencies



Source: CEIC, UBS estimates

Figure 73: Interest rate differential




Source: CEIC, Bloomberg, UBS estimates

Financial Markets


- **Total industrial profit recovered to 4.3% y/y in April** from -3.7% y/y in March, with revenue growth and profit margin both recovering. Total industrial revenue improved to 3.3% y/y in April from -1.2% y/y previously. By sector, profit growth in the mining industry remained deep in contraction y/y, while that of the manufacturing industry rebounded, and the utilities sector improved further.
- **UBS expects MSCI China index target at \$65 in 2024.** UBS equity strategists continue to hold a positive view on the China equity market given trough valuation, low investor positioning, modest policy support and improving earning momentum ahead. Taking into account adjusted EPS forecast for this year, alongside unchanged view on valuation, they update MSCI China index target to \$65 (see [updating MSCI China index target](#)).
- **2024E sector allocations:** UBS equity strategists adopt a barbell strategy with high dividend stocks on the one hand (comprised of select SOE, utility and financials stocks), and internet, property, education, semi-equipment and outbound travel on the other. They shift preferences away from domestic consumption stocks, as they believe a recovery in consumption fundamentals may take a bit longer, while in the event of a grinding market recovery, property and internet sectors may be better positioned. See more in [Shifting sector allocations](#).

Figure 74: A-share market has recovered from the trough since Feb...




Source: CEIC, UBS estimates

Figure 75: ... same with H-share market




Source: CEIC, UBS estimates

Figure 76: Sector performance divergence in the A-share...




Source: Wind, UBS estimates

Figure 77: ... and the H-share market




Source: Wind, UBS estimates

Figure 78: Industrial profit recovered y/y in April



Source: CEIC, UBS estimates

Figure 79: Both revenue growth and margin improved




Source: CEIC, UBS estimates * chart is 3mma basis

Fiscal


- Fiscal revenue weakened further while expenditure rebounded y/y in April.** Headline fiscal revenue declined by 3.7% y/y in April from -2.4% y/y in March (-2.3% y/y in Q1). On a comparable basis (after controlling a high base due to delayed SME tax collection and carry-over of tax cuts since mid-2023), the underlying fiscal revenue grew 2% y/y in Jan-Apr (vs headline -2.7% y/y). Fiscal expenditure rebounded to 6.1% y/y in April from -2.9% y/y in March (+2.9% y/y in Q1). Corporate income tax revenue cooled to 0.7% y/y in April (1% y/y in Q1), while personal income tax slid again to -18.8% y/y on a high base (-4.5% y/y in Q1). As such, April saw a headline fiscal surplus of RMB42bn, smaller than the average level in previous years. Local land revenue declined by another -21% y/y in April from -19% y/y in March (-6.7% y/y in Q1).
- Further progress in addressing LGFV debt issue.** Local governments issued RMB1.39 trillion of special refinancing LG bonds to swap for qualified [LGFV debt](#) and/or pay arrears to corporate suppliers in H2 2023. In 2024, we expect additional issuance of special refinancing LG bonds and banks to increase restructuring of LGFV bank loans, while YTD issuance has been very limited at RMB 84bn. We think the long-term solution (eg, adjustment of central-local fiscal relations and debt structure) may not materialise soon but could possibly be discussed in the upcoming 3rd Plenum (see [NPC takeaway](#) and [Politburo meeting](#)).
- Modest fiscal support in a more explicit way.** China announced a headline general fiscal deficit of 3% of GDP, additional RMB1trn special CGB and RMB3.9trn special LG bonds for 2024. The combined budget deficit (general fiscal + govt funds) on a cash basis is estimated to be 8.2% of GDP (+1.2ppt larger 2023 outturn). We expect the Augmented Fiscal Deficit (AFD) to expand by 1ppt in 2024 after no increase in 2023. The government called for faster issuance of special CGB and special LGB, and is avoiding fiscal tightening as it did in H1 2023. Overall, fiscal support will be more explicit in stronger on-budget spending, especially from central government. We think local government land sales revenue may decline by another 10% in 2024, while off-budget LGFV financing will likely be muted amid the ongoing emphasis of controlling implicit debt risk (see [NPC takeaway](#)).

Figure 80: April fiscal revenue slid but expenditure rebounded




Source: CEIC, UBS estimates.

Figure 81: Fiscal deficit 3% of GDP in 2024, excluding 1 trillion special CGB




Source: CEIC, UBS estimates

Figure 82: Local land sales revenue - 21% y/y in April




Source: CEIC, Wind, UBS estimates

Figure 83: LGFV debt reached RMB 59trn in 2022




Source: CEIC, Wind, UBS estimates

Figure 84: Slow issuance of special LGB in Jan-May



Source: CEIC, UBS estimates

Figure 85: China's AFD to expand by 1ppt in 2024E after no change in 2023



Source: CEIC, Wind, UBS estimates

Macroeconomic data tables

		May-23	Jun-23	Jul-23	Aug-23	Sep-23	Oct-23	Nov-23	Dec-23	Jan-24	Feb-24	Mar-24	Apr-24	May-24
Physical Activity Index (SARS-adjusted)		7.6	4.0	3.2	5.4	7.4	7.2	9.1	8.7	4.9	4.9	1.9	3.0	2.8
Industry		6.9	2.8	4.7	8.9	7.9	8.6	10.2	10.0	8.8	8.8	8.1	12.0	8.0
Elec		7.5	4.4	3.2	2.6	9.2	7.0	9.8	10.1	6.6	6.6	3.9	3.8	5.1
Trans		44.7	27.3	24.5	27.0	34.3	38.3	44.3	38.9	13.7	13.7	8.7	6.8	14.8
Cons		0.3	-2.7	-4.6	-7.1	-4.8	-5.8	-3.2	-3.2	-12.9	-12.9	-20.6	-19.3	-17.9
Agri		3.7	3.4	-1.0	3.9	4.3	4.1	4.3	4.3	2.0	2.0	3.2	3.1	3.0
CPI sa	02=100	163.3	163.5	163.5	163.9	163.8	163.4	163.0	163.2	163.4	163.5	163.3	163.5	163.7
Food	02=100	277.4	281.5	276.2	275.3	273.0	271.2	268.9	269.3	268.6	269.4	268.9	268.3	270.9
Goods	02=100	115.7	115.7	116.0	116.4	116.6	116.6	116.4	116.6	116.8	116.9	116.9	117.1	117.0
Services	02=100	142.4	131.0	131.6	127.8	127.9	129.5	127.1	130.2	130.4	128.3	143.7	143.9	143.9
CPI	y/y%	0.2	0.0	-0.3	0.1	0.0	-0.2	-0.5	-0.3	-0.8	0.7	0.1	0.3	0.3
Food	y/y%	1.0	2.3	-1.7	-1.7	-3.2	-4.0	-4.2	-3.7	-5.9	-0.9	-2.7	-2.7	-2.0
Goods	y/y%	-0.7	-1.5	-0.9	-0.1	0.2	0.3	-0.1	0.1	0.2	0.8	0.6	1.1	0.9
Services	y/y%	0.6	0.6	1.0	1.1	1.1	1.1	0.9	0.9	0.7	1.7	0.8	0.8	0.8
PPI	96=100	129.9	129.2	129.1	130.0	130.0	129.7	129.2	129.3	129.1	128.8	128.0	127.6	127.8
RMI	96=100	172.8	171.7	170.6	172.0	172.5	172.0	171.8	171.8	171.8	171.3	170.2	169.5	169.6
CGPI	96=100	127.8	127.5	127.9	128.6	128.8	128.3	128.2	128.6	128.1	127.6	126.7	126.5	#N/A
Import	96=100	154.1	152.1	148.1	150.8	154.3	157.5	158.3	158.4	157.7	157.6	157.3	154.8	155.4
PPI	y/y%	-4.6	-5.4	-4.4	-3.0	-2.5	-2.6	-3.0	-2.7	-2.5	-2.7	-2.8	-2.5	-1.4
RMI	y/y%	-5.3	-6.5	-6.1	-4.6	-3.6	-3.7	-4.0	-3.8	-3.4	-3.4	-3.5	-3.0	-1.7
CGPI	y/y%	-4.1	-4.5	-3.0	-2.0	-1.4	-2.1	-2.1	-1.8	-2.2	-2.2	-2.3	-1.8	#N/A
Import	y/y%	-10.8	-12.5	-14.4	-11.9	-8.3	-5.9	-1.3	-3.3	-2.9	-1.7	-1.2	-1.1	0.5
M0	RMB bn sa	10,708	10,850	10,943	11,025	11,165	11,267	11,373	11,301	11,258	11,027	11,611	11,760	11,918
M1	RMB bn sa	67,957	67,664	67,606	67,571	67,712	67,536	67,241	67,450	68,892	69,278	68,172	66,807	65,225
M2	RMB bn sa	281,753	283,853	285,442	287,744	289,428	291,623	294,016	294,830	297,152	299,053	300,896	300,479	301,375
Loans	RMB bn sa	227,925	229,311	231,953	233,763	236,146	238,778	241,475	241,504	242,296	244,646	247,486	248,506	251,325
Deposits	RMB bn sa	274,104	275,406	276,817	279,103	280,931	283,552	285,907	288,031	289,160	291,563	292,126	291,085	292,341
M0	y/y%	9.6	9.8	9.9	9.5	10.7	10.2	10.4	8.3	5.9	12.5	11.0	10.8	11.7
M1	y/y%	4.7	3.1	2.3	2.2	2.1	1.9	1.3	1.3	5.9	1.2	1.1	-1.4	-4.2
M2	y/y%	11.6	11.3	10.7	10.6	10.3	10.3	10.0	9.7	8.7	8.7	8.3	7.2	7.0
Loans	y/y%	11.4	11.3	11.1	11.1	10.9	10.9	10.8	10.6	10.4	10.1	9.6	9.6	9.3
Deposits	y/y%	11.6	11.0	10.5	10.5	10.2	10.5	10.2	10.0	9.2	8.4	7.9	6.6	6.7
Reserve money	RMB bn sa	34732	36056	35856	36316	36159	36088	36842	37095	37513	36493	36222	36476	36275
Reserve money (adjusted)	y/y%	6.6	8.9	7.6	8.4	8.1	7.4	9.5	7.4	5.6	8.5	4.5	5.4	5.9
Fixed asset investment	y/y%	2.2	3.3	1.2	2.0	2.5	1.3	2.9	4.0	4.2	4.2	4.7	3.6	3.5
Real FAI	y/y%	3.4	5.3	3.6	3.6	3.5	2.2	3.9	4.6	4.4	4.1	4.6	3.4	2.8
Industrial sales real growth	%y/y	2.7	1.9	1.9	3.0	3.5	5.0	9.8	3.8	6.8	6.8	1.0	5.3	#N/A
Industrial value added growth	%y/y	3.5	4.4	3.7	4.5	4.5	4.6	6.6	6.8	7.0	7.0	4.5	6.7	5.6
Industrial inventories	RMB bn	6090.1	6003.2	6066.4	6127.6	6094.8	6172.5	6237.3	6097.3	6044.7	6044.7	6207.1	6280.5	#N/A
Inventory/sales ratio	%	60.3	60.1	59.8	59.7	59.4	59.0	58.6	61.6	62.3	63.4	64.2	64.3	#N/A
Industrial profits	RMB bn	2668.9	3388.5	3944.0	4655.8	5412.0	6115.4	6982.3	7685.8	914.1	914.1	1505.5	2094.7	#N/A
Profit margin (sa)	%	5.4	5.4	5.5	6.0	6.0	6.4	6.5	6.4	6.1	5.8	5.4	5.3	#N/A
Retail sales	RMB bn	3780.3	3995.1	3676.1	3793.3	3982.6	4333.3	4250.5	4355.0	4065.3	4065.3	3902.0	3569.9	3921.1
Real retail sales	%y/y SARS	12.9	3.5	3.6	5.1	6.2	8.6	11.5	8.4	6.7	5.7	3.4	2.2	3.6
Urban per capita disposable income	RMB sa	2704.0	2704.8	2715.7	2715.2	2721.7	2719.0	2723.8	2717.4	2760.1	2769.5	2792.3	#N/A	#N/A
Urban per capita expenditure	RMB sa	1709.0	1720.5	1742.4	1758.1	1782.5	1748.3	1728.1	1693.0	1745.7	1765.6	1791.8	#N/A	#N/A
Rural cash income	RMB sa	1054.4	1062.7	1065.9	1066.3	1068.5	1081.2	1091.9	1098.2	1099.9	1103.7	1107.7	#N/A	#N/A
Rural cash consumption expenditure	RMB sa	883.5	898.6	907.8	915.7	927.1	910.4	909.8	887.5	915.8	924.7	934.3	#N/A	#N/A
Composite construction index ex land	% y/y	-0.2	-1.2	-4.4	-4.9	-5.1	-6.1	-3.3	-4.2	-9.3	-10.0	-20.6	-18.8	-17.9
Exports	USD bn	283.8	285.3	281.8	284.8	296.7	274.3	292.7	303.5	307.7	220.3	279.7	292.5	302.3
Imports	USD bn	217.6	214.7	201.2	216.5	221.2	218.1	223.3	228.2	222.3	180.6	221.1	220.1	219.7
Trade balance	USD bn	66.3	70.6	80.6	68.3	75.5	56.1	69.5	75.3	85.5	39.7	58.6	72.4	82.6
Real export growth	% y/y	-0.3	-1.8	-4.0	5.9	7.9	7.4	12.0	13.3	20.7	19.6	-1.3	9.8	13.6
Real import growth	% y/y	7.1	6.5	2.4	5.3	2.2	9.4	0.6	3.6	18.9	-6.6	-0.7	9.6	1.3
FDI utilized YTD	USD bn	84.4	98.1	111.8	121.7	131.9	141.2	148.7	161.8	15.9	30.3	42.5	0.0	0.0
FDI utilized monthly sa	USD bn	11.4	14.2	31.7	11.4	11.0	10.9	7.9	5.5	16.2	16.7	33.5	0.0	0.0
FX reserves	USD bn	3176.5	3193.0	3204.3	3160.1	3115.1	3101.2	3171.8	3238.0	3219.3	3225.8	3245.7	3200.8	3232.0
Monthly intervention (adj sa)	USD bn	34.3	20.2	57.4	54.8	71.0	55.1	25.5	24.9	60.3	-14.5	86.6	61.0	46.1
Current account (est)	% GDP	2.3	2.5	2.5	2.4	2.5	2.4	2.5	2.1	2.2	1.8	1.4	1.0	#N/A
FDI	% GDP	1.0	1.0	0.9	0.9	0.8	0.7	0.6	0.7	0.9	1.0	0.9	0.8	#N/A
"Other" capital (residual)	% GDP	-2.2	-2.9	-3.3	-3.8	-4.6	-4.5	-3.1	-1.1	-1.1	-1.4	-1.6	-1.6	-1.5
CN NDF 3M	%	0.6	0.7	0.9	0.7	0.9	1.1	1.2	0.9	1.1	1.3	1.4	1.5	1.8
CN NDF 12M	%	2.3	2.7	2.9	2.7	2.4	2.3	2.5	2.2	2.4	2.5	2.6	2.5	2.9
CN Average CIBOR and REPO 7-day	%	2.0	2.1	2.0	1.9	2.1	2.2	2.2	2.1	2.1	2.0	2.0	2.0	1.9
CN average long yield	%	2.9	2.8	2.8	2.7	2.8	2.8	2.8	2.7	2.6	2.5	2.4	2.4	2.4
SH market		3283.6	3219.7	3216.6	3174.7	3124.8	3052.8	3044.6	2958.9	2880.0	2881.4	3044.4	3058.9	3127.5

Source: UBS estimates. Note: FDI (MOFCOM) in USD term is derived from CNY term since August 2023

World and APAC snapshot

	Real Growth (%YoY)				Consumer Prices (%YoY)				Industrial Production (%YoY)			
	2022	2023	2024F	2025F	2022	2023	2024F	2025F	2022	2023	2024F	2025F
World	3.4	3.3	3.1	3.1	8.4	6.2	5.8	3.9	2.5	1.7	2.1	3.1
Major economies												
US	1.9	2.5	2.3	1.4	8.0	4.1	3.1	2.5	3.4	0.2	-0.2	0.5
Eurozone	3.5	0.5	0.6	1.2	8.4	5.5	2.4	2.1	2.2	-2.0	0.2	1.1
Asia Pacific												
China	3.0	5.2	4.9	4.6	2.0	0.2	0.4	1.4	2.7	4.2	4.0	4.2
Hong Kong	-3.7	3.2	2.5	2.8	1.9	1.8	1.8	2.1	na	na	na	na
India	7.0	8.2	7.0	7.0	6.7	5.4	4.5	4.5	-2.2	9.9	5.6	6.6
Indonesia	5.3	5.0	4.9	5.0	4.1	3.7	3.0	2.5	4.9	4.6	4.1	5.0
Japan	1.0	1.9	0.2	1.0	2.5	3.3	2.4	1.9	0.0	-1.4	0.2	2.8
Malaysia	8.9	3.6	4.1	4.3	3.4	2.5	2.4	2.7	8.1	0.7	-2.7	9.5
Philippines	7.6	5.5	5.7	6.1	5.8	6.0	3.3	2.6	4.9	1.3	5.3	6.1
Singapore	3.8	1.1	2.6	2.7	6.1	4.8	2.7	2.0	2.7	-4.3	-1.2	3.6
Korea	2.6	1.3	2.3	2.1	5.1	3.6	2.2	1.9	4.9	1.1	3.8	2.1
Taiwan	2.6	1.3	3.8	3.1	2.9	2.5	2.3	1.9	-1.5	-13.3	5.5	2.8
Thailand	2.5	1.9	2.8	3.3	6.1	1.2	0.8	1.8	1.3	-3.8	1.6	3.2
Vietnam	8.0	5.2	6.4	6.8	3.2	3.0	3.1	2.9	7.9	3.6	6.7	6.4
Australia	3.9	2.0	1.2	2.1	6.6	5.6	3.3	3.3	0.0	0.4	0.9	1.7
	Current Account (%GDP)				Exchange Rate(LC per \$, end period)***				Policy Rate (% p.a, end period)			
	2022	2023	2024F	2025F	2022	2023	2024F	2025F	2022	2023	2024F	2025F
Major economies												
US	-3.8	-3.5	-3.5	-3.5	--	--	--	--	4.33	5.33	5.08	3.33
Eurozone	-0.7	1.9	2.2	2.4	1.07	1.08	1.05	1.10	2.00	4.00	3.25	2.25
Asia Pacific												
China	2.5	1.4	1.2	1.2	6.96	7.08	7.15	7.00	2.75	2.50	2.50	2.50
Hong Kong	10.2	6.2	6.4	6.4	7.80	7.81	7.75	7.75	4.99	5.15	4.30	3.02
India	-2.0	-0.7	-1.4	-1.8	82.3	82.6	83.0	84.0	6.50	6.50	6.25	6.00
Indonesia	1.0	-0.1	-0.9	-1.1	15731	15416	16000	15800	5.50	6.00	6.25	5.50
Japan	1.9	3.6	4.2	4.8	132.1	140.0	160.0	140.0	-0.10	-0.10	0.25	1.00
Malaysia	3.1	1.6	3.5	3.1	4.41	4.59	4.70	4.60	2.75	3.00	3.00	3.00
Philippines	-4.5	-2.6	-2.0	-2.7	56.1	55.6	57.0	56.0	5.50	6.50	6.00	5.00
Singapore	18.0	19.8	16.9	15.9	1.34	1.32	1.33	1.31	2.53	3.58	3.00	2.00
Korea	1.5	2.1	3.6	3.9	1265	1288	1330	1350	3.25	3.50	3.25	2.00
Taiwan	13.4	13.9	11.7	12.3	30.7	30.7	32.0	31.0	1.75	1.88	2.00	1.63
Thailand	-3.2	1.4	2.9	4.8	34.6	34.4	36.0	35.5	1.25	2.50	2.50	2.25
Vietnam	-0.2	4.5	4.0	4.6	23555	24255	23527	23057	6.00	4.00	4.00	5.00
Australia	3.9	-0.9	-1.1	-1.6	0.68	0.65	0.66	0.66	3.10	4.35	4.35	3.35

Source: CEIC, Haver, UBS estimates. *FY Beginning April

Key global indicators

	2022	2023	2024F	2025F	1Q23	2Q23	3Q23	4Q23	1Q24
Real GDP Growth, % yoy									
World	3.4	3.3	3.1	3.1	2.8	3.7	3.3	3.5	3.5
US	1.9	2.5	2.3	1.4	1.7	2.4	2.9	3.1	2.9
Eurozone	3.5	0.5	0.6	1.2	3.6	3.5	3.4	2.3	1.9
Japan	1.0	1.9	0.2	1.0	2.4	2.2	1.5	1.2	-0.3
China	3.0	5.2	4.9	4.6	4.5	6.3	4.9	5.2	5.3
Non-China Asia	5.6	5.5	5.4	5.4	4.3	5.3	5.6	6.0	6.0
Industrial Production, % yoy									
World	2.5	1.7	2.1	3.1	--	--	--	--	--
US	3.4	0.2	-0.2	0.5	--	--	--	--	--
Eurozone	2.2	-2.0	0.2	1.1	--	--	--	--	--
Japan	0.0	-1.4	0.2	2.8	--	--	--	--	--
China	2.7	4.2	4.0	4.2	2.9	4.5	4.2	5.2	6.1
Non-China Asia	1.3	3.9	4.4	5.5	1.9	1.7	6.7	6.2	4.0
CPI Inflation, % yoy									
World	9.5	7.5	8.2	5.1	--	--	--	--	--
US	8.0	4.1	3.1	2.5	5.7	4.0	3.6	3.2	3.2
Eurozone	8.4	5.5	2.4	2.1	8.0	6.2	5.0	2.7	2.6
Japan	2.5	3.3	2.4	1.9	3.6	3.3	3.2	2.9	2.6
China	2.0	0.2	0.4	1.4	1.3	0.1	-0.1	-0.3	0.0
Non-China Asia	5.4	4.3	3.4	3.3	5.4	3.9	4.5	3.9	3.6
Key commodity prices									
Brent Oil (USD/barrel)	99.0	82.2	83.2	80.0	82.2	77.8	85.9	82.0	81.8
Thermal Coal (US\$/t, Australia FOB)	357	175	122	110	248	160	147	135	127
CRB Index	592.5	546.4	--	--	552.0	546.9	555.1	531.5	521.6
Key interest rates (end period)									
US Fed Funds rate	4.33	5.33	5.08	4.58	4.83	5.08	5.33	5.33	5.33
3M USD Libor	4.77	5.59	5.04	4.54	5.19	5.55	5.66	5.59	5.56
ECB refinancing rate	2.50	4.50	3.75	3.50	3.50	4.00	4.50	4.50	4.50
10-year US treasury	3.88	3.88	4.00	3.95	3.48	3.81	4.59	3.88	4.27
10-year German bond	2.57	2.03	2.00	1.90	2.28	2.39	2.85	2.03	2.29
Key exchange rates (end period)									
EUR/USD	1.07	1.08	1.05	1.10	1.1	1.1	1.1	1.1	1.1
USD/JPY	132	140	160	140	133.1	144.9	148.8	141.4	151.3
CNY/USD	7.0	7.1	7.2	7.0	6.89	7.16	7.30	7.14	7.20

Source: CEIC, Haver and UBS estimates

Required Disclosures

This document has been prepared by UBS Securities Asia Limited, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates, including Credit Suisse AG and its subsidiaries, branches and affiliates are referred to herein as "UBS".

For information on the ways in which UBS manages conflicts and maintains independence of its UBS Global Research product; historical performance information; certain additional disclosures concerning UBS Global Research recommendations; and terms and conditions for certain third party data used in research report, please visit <https://www.ubs.com/disclosures>. Unless otherwise indicated, information and data in this report are based on company disclosures including but not limited to annual, interim, quarterly reports and other company announcements. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission. UBS acts or may act as principal in the debt securities (or in related derivatives) that may be the subject of this report. This recommendation was finalized on: 24 June 2024 03:19 AM GMT. UBS has designated certain UBS Global Research department members as Derivatives Research Analysts where those department members publish research principally on the analysis of the price or market for a derivative, and provide information reasonably sufficient upon which to base a decision to enter into a derivatives transaction. Where Derivatives Research Analysts co-author research reports with Equity Research Analysts or Economists, the Derivatives Research Analyst is responsible for the derivatives investment views, forecasts, and/or recommendations. **Quantitative Research Review:** UBS Global Research publishes a quantitative assessment of its analysts' responses to certain questions about the likelihood of an occurrence of a number of short term factors in a product known as the 'Quantitative Research Review'. Views contained in this assessment on a particular stock reflect only the views on those short term factors which are a different timeframe to the 12-month timeframe reflected in any equity rating set out in this note. For the latest responses, please see the Quantitative Research Review Addendum at the back of this report, where applicable. For previous responses please make reference to (i) previous UBS Global Research reports; and (ii) where no applicable research report was published that month, the Quantitative Research Review which can be found at <https://neo.ubs.com/quantitative>, or contact your UBS sales representative for access to the report or the Quantitative Research Team on qa@ubs.com. A consolidated report which contains all responses is also available and again you should contact your UBS sales representative for details and pricing or the Quantitative Research team on the email above.

Analyst Certification:

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/qualified as research analysts with FINRA. Such analysts may not be associated persons of UBS Securities LLC and therefore are not subject to the FINRA restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.

UBS AG Hong Kong Branch: Ning Zhang, Tao Wang, William Deng. **UBS Securities Co. Limited:** Grace Wang, Jennifer Zhong.

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report. For a complete set of disclosure statements associated with the companies discussed in this report, including information on valuation and risk, please contact UBS Securities LLC, 1285 Avenue of Americas, New York, NY 10019, USA, Attention: Investment Research.

UBS Global Research Disclaimer

This document has been prepared by UBS Securities Asia Limited, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates, including Credit Suisse AG and its subsidiaries, branches and affiliates are referred to herein as "UBS".

Any opinions expressed in this document may change without notice and are only current as of the date of publication. Different areas, groups, and personnel within UBS may produce and distribute separate research products independently of each other. For example, research publications from **UBS CIO** are produced by UBS Global Wealth Management. **UBS Global Research** is produced by UBS Investment Bank. Research methodologies and rating systems of each separate research organization may differ, for example, in terms of investment recommendations, investment horizon, model assumptions, and valuation methods. As a consequence, except for certain economic forecasts (for which UBS CIO and UBS Global Research may collaborate), investment recommendations, ratings, price targets, and valuations provided by each of the separate research organizations may be different, or inconsistent. You should refer to each relevant research product for the details as to their methodologies and rating system. Not all clients may have access to all products from every organization. Each research product is subject to the policies and procedures of the organization that produces it.

This document is provided solely to recipients who are expressly authorized by UBS to receive it. If you are not so authorized you must immediately destroy the document.

UBS Global Research is provided to our clients through UBS Neo, and in certain instances, UBS.com and any other system or distribution method specifically identified in one or more communications distributed through UBS Neo or UBS.com (each a system) as an approved means for distributing UBS Global Research. It may also be made available through third party vendors and distributed by UBS and/or third parties via e-mail or alternative electronic means.

All UBS Global Research is available on UBS Neo. Please contact your UBS sales representative if you wish to discuss your access to UBS Neo. Where UBS Global Research refers to "UBS Evidence Lab Inside" or has made use of data provided by UBS Evidence Lab and you would like to access that data please contact your UBS sales representative. UBS Evidence Lab data is available on UBS Neo. The level and types of services provided by UBS Global Research and UBS Evidence Lab to a client may vary depending upon various factors such as a client's individual preferences as to the frequency and manner of receiving communications, a client's risk profile and investment focus and perspective (e.g., market wide, sector specific, long-term, short-term, etc.), the size and scope of the overall client relationship with UBS Global Research and UBS Evidence Lab and legal and regulatory constraints.

When you receive UBS Global Research through a system, your access and/or use of such UBS Global Research is subject to this UBS Global Research Disclaimer and to the UBS Neo Platform Use Agreement (the "Neo Terms") together with any other relevant terms of use governing the applicable System.

When you receive UBS Global Research via a third party vendor, e-mail or other electronic means, you agree that use shall be subject to this UBS Global Research Disclaimer, the Neo Terms and where applicable the UBS Investment Bank terms of business (<https://www.ubs.com/global/en/investment-bank/regulatory.html>) and to UBS's Terms of Use/Disclaimer (<https://www.ubs.com/global/en/legalinfo2/disclaimer.html>). In addition, you consent to UBS processing your personal data and using cookies in accordance with our Privacy Statement (<https://www.ubs.com/global/en/legalinfo2/privacy.html>) and cookie notice (<https://www.ubs.com/global/en/legal/privacy/users.html>).

If you receive UBS Global Research, whether through a System or by any other means, you agree that you shall not copy, revise, amend, create a derivative work, provide to any third party, or in any way commercially exploit any UBS research provided via UBS Global Research or otherwise, and that you shall not extract data from any research or estimates provided to you via UBS Global Research or otherwise, without the prior written consent of UBS.

In certain circumstances (including for example, if you are an academic or a member of the media) you may receive UBS Global Research otherwise than in the capacity of a client of UBS and you understand and agree that (i) the UBS Global Research is provided to you for information purposes only; (ii) for the purposes of receiving it you are not intended to be and will not be treated as a "client" of UBS for any legal or regulatory purpose; (iii) the UBS Global Research must not be relied on or acted upon for any purpose; and (iv) such content is subject to the relevant disclaimers that follow.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction.

This document is a general communication and is educational in nature; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. By providing this document, none of UBS or its representatives has any responsibility or authority to provide or have provided investment advice in a fiduciary capacity or otherwise. Investments involve risks, and investors should exercise prudence and their own judgment in making their investment decisions. None of UBS or its representatives is suggesting that the recipient or any other person take a specific course of action or any action at all. The recipient should carefully read this document in its entirety and not draw inferences or conclusions from the rating alone. By receiving this document, the recipient acknowledges and agrees with the intended purpose described above and further disclaims any expectation or belief that the information constitutes investment advice to the recipient or otherwise purports to meet the investment objectives of the recipient. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors.

Options, structured derivative products and futures (including OTC derivatives) are not suitable for all investors. Trading in these instruments is considered risky and may be appropriate only for sophisticated investors. Prior to buying or selling an option, and for the complete risks relating to options, you must receive a copy of "The Characteristics and Risks of Standardized Options." You may read the document at <https://www.theocc.com/publications/risks/riskchap1.jsp> or ask your salesperson for a copy. Various theoretical explanations of the risks associated with these instruments have been published. Supporting documentation for any claims, comparisons, recommendations, statistics or other technical data will be supplied upon request. Past performance is not necessarily indicative of future results. Transaction costs may be significant in option strategies calling for multiple purchases and sales of options, such as spreads and straddles. Because of the importance of tax considerations to many options transactions, the investor considering options should consult with his/her tax advisor as to how taxes affect the outcome of contemplated options transactions.

Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.

Prior to making any investment or financial decisions, any recipient of this document or the information should take steps to understand the risk and return of the investment and seek individualized advice from his or her personal financial, legal, tax and other professional advisors that takes into account all the particular facts and circumstances of his or her investment objectives.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in any materials to which this document relates (the "Information"), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. In no circumstances may this document or any of the Information (including any forecast, value, index or other calculated amount ("Values")) be used for any of the following purposes:

- (i) valuation or accounting purposes;
- (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or
- (iii) to measure the performance of any financial instrument including, without limitation, for the purpose of tracking the return or performance of any Value or of defining the asset allocation of portfolio or of computing performance fees.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for any of the above purposes or otherwise rely upon this document or any of the Information.

UBS has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which UBS relies, to manage potential conflicts of interest and control the flow of information within divisions of UBS and among its subsidiaries, branches and affiliates. For further information on the ways in which UBS Global Research manages conflicts and maintains independence of its research products, historical performance information and certain additional disclosures concerning UBS Global Research recommendations, please visit <https://www.ubs.com/disclosures>.

UBS Global Research will initiate, update and cease coverage solely at the discretion of UBS Global Research Management, which will also have sole discretion on the timing and frequency of any published research product. The analysis contained in this document is based on numerous assumptions. All material information in relation to published research reports, such as valuation methodology, risk statements, underlying assumptions (including sensitivity analysis of those assumptions), ratings history etc. as required by the Market Abuse Regulation, can be found on UBS Neo. Different assumptions could result in materially different results.

The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by UBS Global Research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS and/or its divisions as a whole, of which investment banking, sales and trading are a part, and UBS as a whole.

For financial instruments admitted to trading on an EU regulated market: UBS (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms under English law or, if not carried out by UBS in the UK the law of the relevant jurisdiction in which UBS determines it carries out the activity) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

Within the past 12 months UBS may have received or provided investment services and activities or ancillary services as per MiFID II which may have given rise to a payment or promise of a payment in relation to these services from or to this company.

United Kingdom: This material is distributed by UBS AG, London Branch to persons who are eligible counterparties or professional clients. UBS AG, London Branch is authorised by the Prudential Regulation Authority and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. **Europe:** Except as otherwise specified herein, these materials are distributed by UBS Europe SE, a subsidiary of UBS AG, to persons who are eligible counterparties or professional clients (as detailed in the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) Rules and according to MiFID) and are only available to such persons. The information does not apply to, and should not be relied upon by, retail clients. UBS Europe SE is authorised by the European Central Bank (ECB) and regulated by the BaFin and the ECB. **Germany, Luxembourg, the Netherlands, Belgium and Ireland:** Where an analyst of UBS Europe SE has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE. In all cases it is distributed by UBS Europe SE and UBS AG, London Branch. **Turkey:** Distributed by UBS AG, London Branch. No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey. UBS AG, London Branch is not licensed by the Turkish Capital Market Board under the provisions of the Capital Market Law (Law No. 6362). Accordingly, neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the Capital Market Board. However, according to article 15 (d) (ii) of the Decree No. 32, there is no restriction on the purchase or sale of the securities abroad by residents of the Republic of Turkey. **Poland:** Distributed by UBS Europe SE (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce regulated by the Polish Financial Supervision Authority. Where an analyst of UBS Europe SE (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce. **Russia:** Prepared and distributed by UBS Bank (OOO). Should not be construed as an individual Investment Recommendation for the purpose of the Russian Law - Federal Law #39-FZ ON THE SECURITIES MARKET Articles 6.1-6.2. **Switzerland:** Distributed by UBS AG to persons who are institutional investors only. UBS AG is regulated by the Swiss Financial Market Supervisory Authority (FINMA). **Italy:** Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Europe SE, Italy Branch. Where an analyst of UBS Europe SE, Italy Branch has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE, Italy Branch. **France:** Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Europe SE, France Branch. Where an analyst of UBS Europe SE, France Branch has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE, France Branch. **Spain:** Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Europe SE, Spain Branch. Where an analyst of UBS Europe SE, Spain Branch has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE, Spain Branch. **Sweden:** Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Europe SE, Sweden Branch. Where an analyst of UBS Europe SE, Sweden Branch has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE, Sweden Branch. **South Africa:** Distributed by UBS South Africa (Pty) Limited (Registration No. 1995/011140/07), an authorised user of the JSE and an authorised Financial Services Provider (FSP 7328). **Saudi Arabia:** This document has been issued by UBS AG (and/or any of its subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities business under license number 08113-37. **UAE / Dubai:** The information distributed by UBS AG Dubai Branch is only intended for Professional Clients and/or Market Counterparties, as classified under the DFSA rulebook. No other person should act upon this material/communication. The information is not for further distribution within the United Arab Emirates. UBS AG Dubai Branch is regulated by the DFSA in the DIFC. UBS Investment Bank is not licensed to provide banking services in the UAE by the Central Bank of the UAE, nor is it licensed by the UAE Securities and Commodities Authority. **Israel:** This Material is distributed by UBS AG, London Branch. UBS Securities Israel Ltd is a licensed Investment Marketer that is supervised by the Israel Securities Authority (ISA). UBS AG, London Branch and its affiliates incorporated outside Israel are not licensed under the Israeli Advisory Law. UBS may engage among others in issuance of Financial Assets or in distribution of Financial Assets of other issuers for fees or other benefits. UBS AG, London Branch and its affiliates may prefer various Financial Assets to which they have or may have an Affiliation (as such term is defined under the Israeli Advisory Law). Nothing in this Material should be considered as investment advice under the Israeli Advisory Law. This Material is being issued only to and/or is directed only at persons who are Eligible Clients within the meaning of the Israeli Advisory Law, and this Material must not be furnished to, relied on or acted upon by any other persons. **United States:** Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a 'non-US affiliate') to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a report prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this report must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. UBS Securities LLC is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule"), and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule. **Canada:** Distributed by UBS Securities Canada Inc., a registered investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by another affiliate of UBS AG that is registered to conduct business in Canada or is otherwise exempt from registration. **Brazil:** Except as otherwise specified herein, this Material is prepared by UBS Brasil Corretora de Câmbio, Títulos e Valores Mobiliários S.A. (UBS Brasil CCTVM) to persons who are eligible investors residing in Brazil, which are considered to be Professional Investors (Investidores Profissionais), as designated by the applicable regulation, mainly the CVM Resolution No. 30 from the 11th of May 2021 (determines the duty to verify the suitability of products, services and transactions with regards to the client's profile). UBS Brasil CCTVM is a subsidiary of UBS BB Servicos de Assessoria Financeira e Participacoes S.A. ("UBS BB"). UBS BB is an association between UBS AG and Banco do Brasil (through its subsidiary BB – Banco de Investimentos S.A.), of which UBS AG is the majority owner and which provides investment banking services and coverage in Brazil, Argentina, Chile, Paraguay, Peru and Uruguay. UBS Brasil CCTVM is regulated by the Comissão de Valores Mobiliários (CVM) and by the Central Bank of Brazil. Ombudsman: 0800-940-0266/ <https://www.ubs.com/br/pt/ubsbb-investment-bank/ombudsman.html>. UBS may hold relevant financial and commercial interest in relation to the company subject to this Research report. **Hong Kong:** Distributed by UBS Securities Asia Limited. Please contact local licensed persons of UBS Securities Asia Limited in respect of any matters arising from, or in connection with, the analysis or document. **Singapore:** Distributed by UBS Securities Pte. Ltd. [Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Please contact UBS Securities Pte. Ltd., an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110); or UBS AG, Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or document. The recipients of this document represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289). **Japan:** Distributed by UBS Securities Japan Co., Ltd. to professional investors (except as otherwise permitted). Where this report has been prepared by UBS Securities Japan Co., Ltd., UBS Securities Japan Co., Ltd. is the author, publisher and distributor of the report. Distributed by UBS AG, Tokyo Branch to Professional Investors (except as otherwise permitted) in relation to foreign exchange and other banking businesses when relevant. **Australia:** Clients of UBS AG: Distributed by UBS AG (ABN 47 088 129 613 and holder of Australian Financial Services License No. 231087). For all other recipients: Distributed by UBS Securities Australia Ltd (ABN 62 008 586 481 and holder of Australian Financial Services License No. 231098). This document contains general information and/or general advice only and does not constitute personal financial product advice. As such, the Information in this document has been prepared without taking into account any investor's objectives, financial situation or needs, and investors should, before acting on the Information, consider the appropriateness of the Information, having regard to their objectives, financial situation and needs. If the Information contained in this document relates to the acquisition, or potential acquisition of a particular financial product by a 'Retail' client as defined by section 761G of the Corporations Act 2001 where a Product Disclosure Statement would be required, the retail client should obtain and consider the Product Disclosure Statement relating to the product before making any decision about whether to acquire the product. For clients of Credit Suisse AG, Sydney Branch: Credit Suisse AG, Sydney Branch (ABN 17 061 700 712, AFSL 226896) is a separately licensed, related body corporate of UBS AG, Australia Branch and UBS Securities Australia Ltd. Credit Suisse AG, Sydney Branch has entered into an arrangement with UBS

Securities Australia Ltd to allow Credit Suisse AG to provide UBS Global Research to certain Australian domiciled wholesale clients of Credit Suisse AG, Sydney Branch's Wealth Management Division. If you are receiving UBS Global Research from Credit Suisse, Sydney Branch's Wealth Management Division, this UBS Global Research is issued under the license of UBS Securities Australia Limited. All disclosures and disclaimers contained within this document relating to or provided by UBS Securities Australia Ltd also apply to UBS Global Research received by clients of Credit Suisse AG, Sydney Branch's Wealth Management Division.

New Zealand: Distributed by UBS New Zealand Ltd. UBS New Zealand Ltd is not a registered bank in New Zealand. You are being provided with this publication or material because you have indicated to UBS that you are a "wholesale client" within the meaning of section 5C of the Financial Advisers Act 2008 of New Zealand (Permitted Client). This publication or material is not intended for clients who are not Permitted Clients (non-permitted Clients). If you are a non-permitted Client you must not rely on this publication or material. If despite this warning you nevertheless rely on this publication or material, you hereby (i) acknowledge that you may not rely on the content of this publication or material and that any recommendations or opinions in such this publication or material are not made or provided to you, and (ii) to the maximum extent permitted by law (a) indemnify UBS and its associates or related entities (and their respective Directors, officers, agents and Advisors) (each a 'Relevant Person') for any loss, damage, liability or claim any of them may incur or suffer as a result of, or in connection with, your unauthorised reliance on this publication or material and (b) waive any rights or remedies you may have against any Relevant Person for (or in respect of) any loss, damage, liability or claim you may incur or suffer as a result of, or in connection with, your unauthorised reliance on this publication or material. **Korea:** Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This report may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Seoul Branch. This material is intended for professional/institutional clients only and not for distribution to any retail clients. **Malaysia:** This material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (Capital Markets Services License No.: CMSL/A0063/2007). This material is intended for professional/institutional clients only and not for distribution to any retail clients. **India:** Distributed by UBS Securities India Private Ltd. (Corporate Identity Number U67120MH1996PTC097299) 2/F, 3 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. It provides brokerage services bearing SEBI Registration Number: INZ000259830; and Research Analyst services bearing SEBI Registration Number: INH000001204. Name of Compliance Officer Mr. Parameshwaran Shivaramakrishnan, Phone : +912261556151, Email : parameshwaran.s@ubs.com, Name of Grievance Officer Parameshwaran Shivaramakrishnan, Phone : +912261556151, Email: ol-ubs-sec-compliance@ubs.com Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. UBS may have debt holdings or positions in the subject Indian company/companies. UBS may have financial interests (e.g. loan/derivative products, rights to or interests in investments, etc.) in the subject Indian company / companies from time to time. Within the past 12 months, UBS may have received compensation for non-investment banking securities-related services and/or non-securities services from the subject Indian company/companies. The subject company/companies may have been a client/clients of UBS during the 12 months preceding the date of distribution of the research report with respect to investment banking and/or non-investment banking securities-related services and/or non-securities services. With regard to information on associates, please refer to the Annual Report at: https://www.ubs.com/global/en/about_ubs/investor_relations/annualreporting.html **Taiwan:** Except as otherwise specified herein, this material may not be distributed in Taiwan. Information and material on securities/instruments that are traded in a Taiwan organized exchange is deemed to be issued and distributed by UBS Securities Pte. LTD., Taipei Branch, which is licensed and regulated by Taiwan Financial Supervisory Commission. Save for securities/instruments that are traded in a Taiwan organized exchange, this material should not constitute "recommendation" to clients or recipients in Taiwan for the covered companies or any companies mentioned in this document. No portion of the document may be reproduced or quoted by the press or any other person without authorisation from UBS. **Indonesia:** This report is being distributed by PT UBS Sekuritas Indonesia and is delivered by its licensed employee(s), including marketing/sales person, to its client. PT UBS Sekuritas Indonesia, having its registered office at Sequis Tower Level 22 unit 22-1, Jl.Jend. Sudirman, kav.71, SCBD lot 11B, Jakarta 12190. Indonesia, is a subsidiary company of UBS AG and licensed under Capital Market Law no. 8 year 1995, a holder of broker-dealer and underwriter licenses issued by the Capital Market and Financial Institution Supervisory Agency (now Otoritas Jasa Keuangan/OJK). PT UBS Sekuritas Indonesia is also a member of Indonesia Stock Exchange and supervised by Otoritas Jasa Keuangan (OJK). Neither this report nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens except in compliance with applicable Indonesian capital market laws and regulations. This report is not an offer of securities in Indonesia and may not be distributed within the territory of the Republic of Indonesia or to Indonesian citizens in circumstance which constitutes an offering within the meaning of Indonesian capital market laws and regulations.

The disclosures contained in research documents produced by UBS AG, London Branch or UBS Europe SE shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this document in whole or in part without the written permission of UBS and in any event UBS accepts no liability whatsoever for any redistribution of this document or its contents or the actions of third parties in this respect. Images may depict objects or elements that are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2024. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

